Insider transactions

EDGAR

Xilio Therapeutics, Inc.

Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.

A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.

Window: transactions dated on or after 2025-11-20.

Open-market purchases (code P)
1 transactions, 5,000 shares
Sum of shares × price per share: 43,950
Open-market sales (code S)
2 transactions, 8,856 shares
Sum of shares × price per share: 5,696.1792

Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.

Showing 1–50 of 79

Insider transactions, newest first, as filed on SEC Forms 3, 4 and 5
DateReporting ownerCodeAcquired or disposedSharesPrice per share, as filedValue (derived)Shares owned afterDirect or indirectRule 10b5-1 boxNotesSource
2026-10-01 Filed 2026-10-02Houvras Yariv Officer: CHIEF MEDICAL OFFICER
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (105,000) — exercise price 8.91
Acquired (A)105,0000—105,000Direct (D) No
F1
  • F1 The option was granted on October 1, 2026 and will vest with respect to 25% of the shares of common stock underlying the stock option on September 28, 2027, and the remaining 75% of the shares of common stock underlying the stock option will continue to vest in 36 equal monthly installments thereafter.
Open filing 0001193125-26-412466 Read from the filing’s XML Dispute this row
2026-06-11 Filed 2026-06-12Brennan Aoife Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (5,000) — exercise price 7.99
Acquired (A)5,0000—5,000Direct (D) No
F1
  • F1 The option was granted on June 11, 2026 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 11, 2027 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date.
Open filing 0001193125-26-269395 Read from the filing’s XML Dispute this row
2026-06-11 Filed 2026-06-12Bonstein Sara Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (5,000) — exercise price 7.99
Acquired (A)5,0000—5,000Direct (D) No
F1
  • F1 The option was granted on June 11, 2026 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 11, 2027 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date.
Open filing 0001193125-26-269396 Read from the filing’s XML Dispute this row
2026-06-11 Filed 2026-06-12Shannon James Samuel Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (5,000) — exercise price 7.99
Acquired (A)5,0000—5,000Direct (D) No
F1
  • F1 The option was granted on June 11, 2026 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 11, 2027 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date.
Open filing 0001193125-26-269400 Read from the filing’s XML Dispute this row
2026-06-11 Filed 2026-06-12ROSS ROBERT W. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (5,000) — exercise price 7.99
Acquired (A)5,0000—5,000Direct (D) No
F1
  • F1 The option was granted on June 11, 2026 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 11, 2027 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date.
Open filing 0001193125-26-269397 Read from the filing’s XML Dispute this row
2026-06-11 Filed 2026-06-12Xu Yuan Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (5,000) — exercise price 7.99
Acquired (A)5,0000—5,000Direct (D) No
F1
  • F1 The option was granted on June 11, 2026 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 11, 2027 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date.
Open filing 0001193125-26-269398 Read from the filing’s XML Dispute this row
2026-06-11 Filed 2026-06-12Curran Daniel J. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (5,000) — exercise price 7.99
Acquired (A)5,0000—5,000Direct (D) No
F1
  • F1 The option was granted on June 11, 2026 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 11, 2027 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date.
Open filing 0001193125-26-269401 Read from the filing’s XML Dispute this row
2026-06-11 Filed 2026-06-12Bello Akintunde Olatokumbo Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (5,000) — exercise price 7.99
Acquired (A)5,0000—5,000Direct (D) No
F1
  • F1 The option was granted on June 11, 2026 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 11, 2027 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date.
Open filing 0001193125-26-269399 Read from the filing’s XML Dispute this row
2026-04-15 Filed 2026-04-16Blanchard Cheryl R Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (10,000) — exercise price 8.40
Acquired (A)10,0000—10,000Direct (D) No
F1
  • F1 The option was granted on April 15, 2026 and will vest in three equal installments on April 15, 2027, April 15, 2028 and April 15, 2029, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date.
Open filing 0001193125-26-159316 Read from the filing’s XML Dispute this row
2026-03-26 Filed 2026-03-30Shannon James Samuel Director
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)5,0008.79
43,950

Derived: shares × price per share. Exact value 43950.00.

10,000Direct (D) No
F1, F2
  • F1 The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $8.6758 to $9.2499, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.
  • F2 The number of shares beneficially owned reflects the 1-for-14 reverse stock split effected March 13, 2026.
Open filing 0001193125-26-131745 Read from the filing’s XML Dispute this row
2026-02-13 Filed 2026-02-17GILEAD SCIENCES, INC. 10% owner
P

Open market or private purchase of non-derivative or derivative security

Derivative security: Prefunded Warrants (right to buy) — underlying Common Stock (3,739,000) — exercise price 0.0001
Acquired (A)3,739,0000.5349
1,999,991.1

Derived: shares × price per share. Exact value 1999991.1000.

40,384,266Direct (D) No
F1
  • F1 The Prefunded Warrants are exercisable at any time on or after the date of issuance and have no expiration date. A holder of Prefunded Warrants may not exercise such warrants if, after giving effect to such exercise, the holder and its affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, more than 19.99% of the outstanding shares of Common Stock of the Issuer.
Open filing 0001123292-26-000187 Read from the filing’s XML Dispute this row
2026-01-02 Filed 2026-01-05Brennan Kevin M. Officer: SVP, FINANCE AND ACCOUNTING
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)1,8260.6432
1,174.4832

Derived: shares × price per share. Exact value 1174.4832.

6,371Direct (D) Yes
F2
  • F2 The reported sale of 1,826 shares occurred automatically in a sell to cover transaction pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 8, 2024 solely to cover tax withholding obligations in connection with the vesting of restricted stock units.
Open filing 0001193125-26-002518 Read from the filing’s XML Dispute this row
2026-01-02 Filed 2026-01-05Frankenfield Christopher James Officer: Chief Financial Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)7,0300.6432
4,521.696

Derived: shares × price per share. Exact value 4521.6960.

24,766Direct (D) Yes
F2
  • F2 The reported sale of 7,030 shares occurred automatically in a sell to cover transaction pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 8, 2024 solely to cover tax withholding obligations in connection with the vesting of restricted stock units.
Open filing 0001193125-26-002517 Read from the filing’s XML Dispute this row
2026-01-01 Filed 2026-01-05Brennan Kevin M. Officer: SVP, FINANCE AND ACCOUNTING
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)5,000——8,197Direct (D) Yes
F1
  • F1 Restricted stock units (RSUs) convert to stock on a one-for-one basis.
Open filing 0001193125-26-002518 Read from the filing’s XML Dispute this row
2026-01-01 Filed 2026-01-05Brennan Kevin M. Officer: SVP, FINANCE AND ACCOUNTING
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Units — underlying Common Stock (5,000)
Disposed (D)5,0000—10,000Direct (D) Yes
F1, F6
  • F1 Restricted stock units (RSUs) convert to stock on a one-for-one basis.
  • F6 These RSUs were granted on January 1, 2024 and vest in four equal annual installments beginning on January 1, 2025.
Open filing 0001193125-26-002518 Read from the filing’s XML Dispute this row
2026-01-01 Filed 2026-01-05Russo Rene Director · Officer: PRESIDENT AND CEO
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)44,250——325,422Direct (D) No
F1
  • F1 Restricted stock units (RSUs) convert to stock on a one-for-one basis.
Open filing 0001193125-26-002512 Read from the filing’s XML Dispute this row
2026-01-01 Filed 2026-01-05Russo Rene Director · Officer: PRESIDENT AND CEO
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Units — underlying Common Stock (44,250)
Disposed (D)44,2500—88,500Direct (D) No
F1, F5
  • F1 Restricted stock units (RSUs) convert to stock on a one-for-one basis.
  • F5 These RSUs were granted on January 1, 2024 and vest in four equal annual installments beginning on January 1, 2025.
Open filing 0001193125-26-002512 Read from the filing’s XML Dispute this row
2026-01-01 Filed 2026-01-05Luptakova Katarina Officer: CHIEF MEDICAL OFFICER
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)16,625——33,250Direct (D) No
F1
  • F1 Restricted stock units (RSUs) convert to stock on a one-for-one basis.
Open filing 0001193125-26-002520 Read from the filing’s XML Dispute this row
2026-01-01 Filed 2026-01-05Luptakova Katarina Officer: CHIEF MEDICAL OFFICER
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Units — underlying Common Stock (16,625)
Disposed (D)16,6250—33,250Direct (D) No
F1, F5
  • F1 Restricted stock units (RSUs) convert to stock on a one-for-one basis.
  • F5 These RSUs were granted on January 1, 2024 and vest in four equal annual installments beginning on January 1, 2025.
Open filing 0001193125-26-002520 Read from the filing’s XML Dispute this row
2026-01-01 Filed 2026-01-05Frankenfield Christopher James Officer: Chief Financial Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)19,375——31,796Direct (D) Yes
F1
  • F1 Restricted stock units (RSUs) convert to stock on a one-for-one basis.
Open filing 0001193125-26-002517 Read from the filing’s XML Dispute this row
2026-01-01 Filed 2026-01-05Frankenfield Christopher James Officer: Chief Financial Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Units — underlying Common Stock (19,375)
Disposed (D)19,3750—38,750Direct (D) Yes
F1, F6
  • F1 Restricted stock units (RSUs) convert to stock on a one-for-one basis.
  • F6 These RSUs were granted on January 1, 2024 and vest in four equal annual installments beginning on January 1, 2025.
Open filing 0001193125-26-002517 Read from the filing’s XML Dispute this row
2025-12-31 Filed 2026-01-05Brennan Kevin M. Officer: SVP, FINANCE AND ACCOUNTING
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (95,221) — exercise price 0.841
Acquired (A)95,2210—95,221Direct (D) Yes
F3, F4, F5
  • F3 On October 8, 2025, the Board of Directors (the Board) approved the adoption of the Xilio Therapeutics, Inc. 2025 Stock Incentive Plan (the 2025 Plan), subject to stockholder approval of the adoption of the 2025 Plan. On October 8, 2025, the Compensation Committee of the Board granted these options (referred to as Tranche 3 Options in the 2025 Plan) to the Reporting Person, subject to stockholder approval of the adoption of the 2025 Plan. The stockholders approved the adoption of the 2025 Plan on November 21, 2025. On December 31, 2025, the performance criteria for a portion of the Tranche 3 Options was met.
  • F4 The portion of Tranche 3 Options that achieved the vesting condition s equal to the percentage of the Series B Warrants exercised and/or cancelled due to the receipt by Xilio Therapeutics, Inc. of Non-Dilutive Capital (as defined in the Series B Warrants) by December 31, 2025.
  • F5 This option vests in three (3) equal annual installments over the three-year period beginning on December 31, 2025, subject to the Reporting Person's continued service to the registrant through each applicable vesting date.
Open filing 0001193125-26-002518 Read from the filing’s XML Dispute this row
2025-12-31 Filed 2026-01-05Russo Rene Director · Officer: PRESIDENT AND CEO
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (1,500,258) — exercise price 0.841
Acquired (A)1,500,2580—1,500,258Direct (D) No
F2, F3, F4
  • F2 On October 8, 2025, the Board of Directors (the Board) approved the adoption of the Xilio Therapeutics, Inc. 2025 Stock Incentive Plan (the 2025 Plan), subject to stockholder approval of the adoption of the 2025 Plan. On October 8, 2025, the Compensation Committee of the Board granted these options (referred to as Tranche 3 Options in the 2025 Plan) to the Reporting Person, subject to stockholder approval of the adoption of the 2025 Plan. The stockholders approved the adoption of the 2025 Plan on November 21, 2025. On December 31, 2025, the performance criteria for a portion of the Tranche 3 Options was met.
  • F3 The portion of Tranche 3 Options that achieved the vesting condition is equal to the percentage of the Series B Warrants exercised and/or cancelled due to the receipt by Xilio Therapeutics, Inc. of Non-Dilutive Capital (as defined in the Series B Warrants) by December 31, 2025.
  • F4 This option vests in three (3) equal annual installments over the three-year period beginning on December 31, 2025, subject to the Reporting Person's continued service to the registrant through each applicable vesting date.
Open filing 0001193125-26-002512 Read from the filing’s XML Dispute this row
2025-12-31 Filed 2026-01-05Luptakova Katarina Officer: CHIEF MEDICAL OFFICER
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (451,885) — exercise price 0.841
Acquired (A)451,8850—451,885Direct (D) No
F2, F3, F4
  • F2 On October 8, 2025, the Board of Directors (the Board) approved the adoption of the Xilio Therapeutics, Inc. 2025 Stock Incentive Plan (the 2025 Plan), subject to stockholder approval of the adoption of the 2025 Plan. On October 8, 2025, the Compensation Committee of the Board granted these options (referred to as Tranche 3 Options in the 2025 Plan) to the Reporting Person, subject to stockholder approval of the adoption of the 2025 Plan. The stockholders approved the adoption of the 2025 Plan on November 21, 2025. On December 31, 2025, the performance criteria for a portion of the Tranche 3 Options was met.
  • F3 The portion of Tranche 3 Options that achieved the vesting condition is equal to the percentage of the Series B Warrants exercised and/or cancelled due to the receipt by Xilio Therapeutics, Inc. of Non-Dilutive Capital (as defined in the Series B Warrants) by December 31, 2025.
  • F4 This option vests in three (3) equal annual installments over the three-year period beginning on December 31, 2025, subject to the Reporting Person's continued service to the registrant through each applicable vesting date.
Open filing 0001193125-26-002520 Read from the filing’s XML Dispute this row
2025-12-31 Filed 2026-01-05Frankenfield Christopher James Officer: Chief Financial Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (668,789) — exercise price 0.841
Acquired (A)668,7890—668,789Direct (D) Yes
F3, F4, F5
  • F3 On October 8, 2025, the Board of Directors (the Board) approved the adoption of the Xilio Therapeutics, Inc. 2025 Stock Incentive Plan (the 2025 Plan), subject to stockholder approval of the adoption of the 2025 Plan. On October 8, 2025, the Compensation Committee of the Board granted these options (referred to as Tranche 3 Options in the 2025 Plan) to the Reporting Person, subject to stockholder approval of the adoption of the 2025 Plan. The stockholders approved the adoption of the 2025 Plan on November 21, 2025. On December 31, 2025, the performance criteria for a portion of the Tranche 3 Options was met.
  • F4 The portion of Tranche 3 Options that achieved the vesting condition is equal to the percentage of the Series B Warrants exercised and/or cancelled due to the receipt by Xilio Therapeutics, Inc. of Non-Dilutive Capital (as defined in the Series B Warrants) by December 31, 2025.
  • F5 This option vests in three (3) equal annual installments over the three-year period beginning on December 31, 2025, subject to the Reporting Person's continued service to the registrant through each applicable vesting date.
Open filing 0001193125-26-002517 Read from the filing’s XML Dispute this row
2025-11-26 Filed 2025-12-01GILEAD SCIENCES, INC. 10% owner
X

Exercise of in-the-money or at-the-money derivative security

Derivative security: Prefunded Warrants (right to buy) — underlying Common Stock (13,335,000) — exercise price 0.0001
Acquired (A)13,335,0000.7499
9,999,916.5

Derived: shares × price per share. Exact value 9999916.5000.

36,645,266Direct (D) No
F1, F2
  • F1 The Reporting Person acquired 13,335,000 Prefunded Warrants upon the exercise of an equal number of Series B Warrants at an exercise price of $0.7499 per warrant. A holder of either such warrant may not exercise such warrant if, after giving effect to such exercise, the holder and its affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, more than 19.99% of the outstanding shares of Common Stock of the Issuer (the Common Stock).
  • F2 The Prefunded Warrants are exercisable at any time on or after the date of issuance and have no expiration date.
Open filing 0001123292-25-000675 Read from the filing’s XML Dispute this row
2025-11-26 Filed 2025-12-01GILEAD SCIENCES, INC. 10% owner
X

Exercise of in-the-money or at-the-money derivative security

Derivative security: Series B Warrants (right to buy) — underlying Common Stock (13,335,000) — exercise price 0.7499
Disposed (D)13,335,0000—0Direct (D) No
F1, F3, F4
  • F1 The Reporting Person acquired 13,335,000 Prefunded Warrants upon the exercise of an equal number of Series B Warrants at an exercise price of $0.7499 per warrant. A holder of either such warrant may not exercise such warrant if, after giving effect to such exercise, the holder and its affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, more than 19.99% of the outstanding shares of Common Stock of the Issuer (the Common Stock).
  • F3 The exercise price of the Series B Warrants was $0.75 per share of Common Stock. Because the Reporting Person chose to receive Prefunded Warrants in lieu of Common Stock upon exercise of the Series B Warrants, the exercise price was $0.75 less $0.0001 per share.
  • F4 The Series B Warrants were exercisable at any time on or after November 1, 2025 and would have expired on December 2, 2025, provided that if the closing price of the Common Stock was below the exercise price on such date, the exercise price would have reset to the closing price on December 1, 2025 and the expiration time would have been extended to December 31, 2025.
Open filing 0001123292-25-000675 Read from the filing’s XML Dispute this row
2025-11-21 Filed 2025-11-25Luptakova Katarina Officer: CHIEF MEDICAL OFFICER
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (625,000) — exercise price 0.841
Acquired (A)625,0000—625,000Direct (D) No
F1, F2
  • F1 On October 8, 2025, the Board of Directors (the Board) approved the adoption of the Xilio Therapeutics, Inc. 2025 Stock Incentive Plan (the 2025 Plan), subject to stockholder approval of the adoption of the 2025 Plan. On October 8, 2025, the Compensation Committee of the Board granted these options (referred to as Tranche 1 Options in the 2025 Plan) to the Reporting Person, subject to stockholder approval of the adoption of the 2025 Plan. The stockholders approved the adoption of the 2025 Plan on November 21, 2025.
  • F2 The options vest in 36 equal monthly installments over the three-year period beginning on December 21, 2025, subject to the Reporting Person's continued service to the registrant through each applicable vesting date.
Open filing 0001193125-25-297205 Read from the filing’s XML Dispute this row
2025-11-21 Filed 2025-11-25Luptakova Katarina Officer: CHIEF MEDICAL OFFICER
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (right to buy) — underlying Common Stock (44,210) — exercise price 9.69
Disposed (D)44,210——0Direct (D) No
F4, F3
  • F4 The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case the original exercise price must be paid (the Option Repricing). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect.
  • F3 This option was granted on December 7, 2021 and vested on December 2, 2022 with respect to 25% of the shares of common stock underlying the stock option. The remaining 75% of the shares of common stock underlying the stock option continues to vest in 36 equal monthly installments thereafter through December 2, 2025.
Open filing 0001193125-25-297205 Read from the filing’s XML Dispute this row
2025-11-21 Filed 2025-11-25Luptakova Katarina Officer: CHIEF MEDICAL OFFICER
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (44,210) — exercise price 1.50
Acquired (A)44,210——44,210Direct (D) No
F4, F3
  • F4 The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case the original exercise price must be paid (the Option Repricing). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect.
  • F3 This option was granted on December 7, 2021 and vested on December 2, 2022 with respect to 25% of the shares of common stock underlying the stock option. The remaining 75% of the shares of common stock underlying the stock option continues to vest in 36 equal monthly installments thereafter through December 2, 2025.
Open filing 0001193125-25-297205 Read from the filing’s XML Dispute this row
2025-11-21 Filed 2025-11-25Luptakova Katarina Officer: CHIEF MEDICAL OFFICER
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (right to buy) — underlying Common Stock (15,000) — exercise price 2.37
Disposed (D)15,000——0Direct (D) No
F4, F5
  • F4 The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case the original exercise price must be paid (the Option Repricing). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect.
  • F5 This option was granted on November 1, 2022. The shares underlying the option began vesting on December 1, 2022 and continue to vest in equal monthly installments thereafter through November 1, 2026.
Open filing 0001193125-25-297205 Read from the filing’s XML Dispute this row
2025-11-21 Filed 2025-11-25Luptakova Katarina Officer: CHIEF MEDICAL OFFICER
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (15,000) — exercise price 1.50
Acquired (A)15,000——15,000Direct (D) No
F4, F5
  • F4 The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case the original exercise price must be paid (the Option Repricing). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect.
  • F5 This option was granted on November 1, 2022. The shares underlying the option began vesting on December 1, 2022 and continue to vest in equal monthly installments thereafter through November 1, 2026.
Open filing 0001193125-25-297205 Read from the filing’s XML Dispute this row
2025-11-21 Filed 2025-11-25Luptakova Katarina Officer: CHIEF MEDICAL OFFICER
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (right to buy) — underlying Common Stock (35,000) — exercise price 2.69
Disposed (D)35,000——0Direct (D) No
F4, F6
  • F4 The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case the original exercise price must be paid (the Option Repricing). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect.
  • F6 This option was granted on January 1, 2023. The shares underlying the option began vesting on February 1, 2023 and continue to vest in equal monthly installments thereafter through January 1, 2027.
Open filing 0001193125-25-297205 Read from the filing’s XML Dispute this row
2025-11-21 Filed 2025-11-25Luptakova Katarina Officer: CHIEF MEDICAL OFFICER
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (35,000) — exercise price 1.50
Acquired (A)35,000——35,000Direct (D) No
F4, F6
  • F4 The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case the original exercise price must be paid (the Option Repricing). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect.
  • F6 This option was granted on January 1, 2023. The shares underlying the option began vesting on February 1, 2023 and continue to vest in equal monthly installments thereafter through January 1, 2027.
Open filing 0001193125-25-297205 Read from the filing’s XML Dispute this row
2025-11-21 Filed 2025-11-25Luptakova Katarina Officer: CHIEF MEDICAL OFFICER
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (right to buy) — underlying Common Stock (25,000) — exercise price 2.785
Disposed (D)25,000——0Direct (D) No
F4, F7
  • F4 The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case the original exercise price must be paid (the Option Repricing). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect.
  • F7 Immediately exercisable.
Open filing 0001193125-25-297205 Read from the filing’s XML Dispute this row
2025-11-21 Filed 2025-11-25Luptakova Katarina Officer: CHIEF MEDICAL OFFICER
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (25,000) — exercise price 1.50
Acquired (A)25,000——25,000Direct (D) No
F4, F7
  • F4 The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case the original exercise price must be paid (the Option Repricing). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect.
  • F7 Immediately exercisable.
Open filing 0001193125-25-297205 Read from the filing’s XML Dispute this row
2025-11-21 Filed 2025-11-25Luptakova Katarina Officer: CHIEF MEDICAL OFFICER
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (right to buy) — underlying Common Stock (106,000) — exercise price 2.79
Disposed (D)106,000——0Direct (D) No
F4, F8
  • F4 The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case the original exercise price must be paid (the Option Repricing). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect.
  • F8 This option was granted on September 5, 2023. The shares underlying the option began vesting on October 1, 2023 and continue to vest in equal monthly installments thereafter through September 1, 2027.
Open filing 0001193125-25-297205 Read from the filing’s XML Dispute this row
2025-11-21 Filed 2025-11-25Luptakova Katarina Officer: CHIEF MEDICAL OFFICER
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (106,000) — exercise price 1.50
Acquired (A)106,000——106,000Direct (D) No
F4, F8
  • F4 The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case the original exercise price must be paid (the Option Repricing). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect.
  • F8 This option was granted on September 5, 2023. The shares underlying the option began vesting on October 1, 2023 and continue to vest in equal monthly installments thereafter through September 1, 2027.
Open filing 0001193125-25-297205 Read from the filing’s XML Dispute this row
2025-11-21 Filed 2025-11-25Brennan Kevin M. Officer: SVP, FINANCE AND ACCOUNTING
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (131,700) — exercise price 0.841
Acquired (A)131,7000—131,700Direct (D) No
F1, F2
  • F1 On October 8, 2025, the Board of Directors (the Board) approved the adoption of the Xilio Therapeutics, Inc. 2025 Stock Incentive Plan (the 2025 Plan), subject to stockholder approval of the adoption of the 2025 Plan. On October 8, 2025, the Compensation Committee of the Board granted these options (referred to as Tranche 1 Options in the 2025 Plan) to the Reporting Person, subject to stockholder approval of the adoption of the 2025 Plan. The stockholders approved the adoption of the 2025 Plan on November 21, 2025.
  • F2 This option vests in 36 equal monthly installments over the three-year period beginning on December 21, 2025, subject to the Reporting Person's continued service to the registrant through each applicable vesting date.
Open filing 0001193125-25-297207 Read from the filing’s XML Dispute this row
2025-11-21 Filed 2025-11-25Brennan Kevin M. Officer: SVP, FINANCE AND ACCOUNTING
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (right to buy) — underlying Common Stock (55,000) — exercise price 3.17
Disposed (D)55,000——0Direct (D) No
F4, F3
  • F4 The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.00 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case the original exercise price must be paid (the Option Repricing). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect.
  • F3 This option was granted on April 1, 2023 and vested on March 30, 2024 with respect to 25% of the shares of common stock underlying the stock option. The remaining 75% of the shares of common stock underlying the stock option continues to vest in 36 equal monthly installments thereafter through March 30, 2027.
Open filing 0001193125-25-297207 Read from the filing’s XML Dispute this row
2025-11-21 Filed 2025-11-25Brennan Kevin M. Officer: SVP, FINANCE AND ACCOUNTING
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (55,000) — exercise price 1.00
Acquired (A)55,000——55,000Direct (D) No
F4, F3
  • F4 The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.00 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case the original exercise price must be paid (the Option Repricing). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect.
  • F3 This option was granted on April 1, 2023 and vested on March 30, 2024 with respect to 25% of the shares of common stock underlying the stock option. The remaining 75% of the shares of common stock underlying the stock option continues to vest in 36 equal monthly installments thereafter through March 30, 2027.
Open filing 0001193125-25-297207 Read from the filing’s XML Dispute this row
2025-11-21 Filed 2025-11-25Brennan Kevin M. Officer: SVP, FINANCE AND ACCOUNTING
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (right to buy) — underlying Common Stock (25,000) — exercise price 2.785
Disposed (D)25,000——0Direct (D) No
F4, F5
  • F4 The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.00 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case the original exercise price must be paid (the Option Repricing). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect.
  • F5 Immediately exercisable.
Open filing 0001193125-25-297207 Read from the filing’s XML Dispute this row
2025-11-21 Filed 2025-11-25Brennan Kevin M. Officer: SVP, FINANCE AND ACCOUNTING
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (25,000) — exercise price 1.00
Acquired (A)25,000——25,000Direct (D) No
F4, F5
  • F4 The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.00 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case the original exercise price must be paid (the Option Repricing). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect.
  • F5 Immediately exercisable.
Open filing 0001193125-25-297207 Read from the filing’s XML Dispute this row
2025-11-21 Filed 2025-11-25Brennan Kevin M. Officer: SVP, FINANCE AND ACCOUNTING
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (right to buy) — underlying Common Stock (20,000) — exercise price 1.08
Disposed (D)20,000——0Direct (D) No
F4, F6
  • F4 The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.00 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case the original exercise price must be paid (the Option Repricing). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect.
  • F6 This option was granted on May 1, 2024. The shares underlying the option began vesting on June 1, 2024 and continue to vest in equal monthly installments thereafter through May 1, 2028.
Open filing 0001193125-25-297207 Read from the filing’s XML Dispute this row
2025-11-21 Filed 2025-11-25Brennan Kevin M. Officer: SVP, FINANCE AND ACCOUNTING
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (20,000) — exercise price 1.00
Acquired (A)20,000——20,000Direct (D) No
F4, F6
  • F4 The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.00 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case the original exercise price must be paid (the Option Repricing). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect.
  • F6 This option was granted on May 1, 2024. The shares underlying the option began vesting on June 1, 2024 and continue to vest in equal monthly installments thereafter through May 1, 2028.
Open filing 0001193125-25-297207 Read from the filing’s XML Dispute this row
2025-11-21 Filed 2025-11-25Russo Rene Director · Officer: PRESIDENT AND CEO
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (2,075,000) — exercise price 0.841
Acquired (A)2,075,0000—2,075,000Direct (D) No
F1, F2
  • F1 On October 8, 2025, the Board of Directors (the Board) approved the adoption of the Xilio Therapeutics, Inc. 2025 Stock Incentive Plan (the 2025 Plan), subject to stockholder approval of the adoption of the 2025 Plan. On October 8, 2025, the Compensation Committee of the Board granted these options (referred to as Tranche 1 Options in the 2025 Plan) to the Reporting Person, subject to stockholder approval of the adoption of the 2025 Plan. The stockholders approved the adoption of the 2025 Plan on November 21, 2025.
  • F2 The options vest in 36 equal monthly installments over the three-year period beginning on December 21, 2025, subject to the Reporting Person's continued service to the registrant through each applicable vesting date.
Open filing 0001193125-25-297203 Read from the filing’s XML Dispute this row
2025-11-21 Filed 2025-11-25Russo Rene Director · Officer: PRESIDENT AND CEO
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (right to buy) — underlying Common Stock (239,703) — exercise price 5.51
Disposed (D)239,703——0Direct (D) No
F4, F3
  • F4 The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case, the original exercise price must be paid (the Option Repricing). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect.
  • F3 Immediately exercisable.
Open filing 0001193125-25-297203 Read from the filing’s XML Dispute this row
2025-11-21 Filed 2025-11-25Russo Rene Director · Officer: PRESIDENT AND CEO
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (239,703) — exercise price 1.50
Acquired (A)239,703——239,703Direct (D) No
F4, F3
  • F4 The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case, the original exercise price must be paid (the Option Repricing). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect.
  • F3 Immediately exercisable.
Open filing 0001193125-25-297203 Read from the filing’s XML Dispute this row
2025-11-21 Filed 2025-11-25Russo Rene Director · Officer: PRESIDENT AND CEO
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (right to buy) — underlying Common Stock (473,334) — exercise price 5.89
Disposed (D)473,334——0Direct (D) No
F4, F3
  • F4 The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case, the original exercise price must be paid (the Option Repricing). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect.
  • F3 Immediately exercisable.
Open filing 0001193125-25-297203 Read from the filing’s XML Dispute this row
2025-11-21 Filed 2025-11-25Russo Rene Director · Officer: PRESIDENT AND CEO
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (473,334) — exercise price 1.50
Acquired (A)473,334——473,334Direct (D) No
F4, F3
  • F4 The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case, the original exercise price must be paid (the Option Repricing). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect.
  • F3 Immediately exercisable.
Open filing 0001193125-25-297203 Read from the filing’s XML Dispute this row

Institutional holders (Form 13F)

Quarter ending 2026-09-30: 8,925 filings read, the latest filed 2026-11-19. Prior quarter ending 2026-06-30: 9,176 filings read.

Showing 1–30 of 30

Institutional holders, largest position first, as filed
ManagerShares or principalValue as filedChange from the prior quarterSource
Bain Capital Life Sciences Investors, LLC 664,021 SH6,009,390 dollarsUnchanged Prior quarter: 664,021Open filing 0001193125-26-462089 Filed 2026-11-16 Dispute this row
GILEAD SCIENCES, INC. 650,389 SH5,886,020 dollarsUnchanged Prior quarter: 650,389Open filing 0001123292-26-001479 Filed 2026-11-06 Dispute this row
ORBIMED ADVISORS LLC 592,300 SH5,360,315 dollarsUnchanged Prior quarter: 592,300Open filing 0001172661-26-005349 Filed 2026-11-16 Dispute this row
ADAGE CAPITAL PARTNERS GP, L.L.C. 464,598 SH4,204,612 dollarsHigher by 353,057 Prior quarter: 111,541Open filing 0001172661-26-005200 Filed 2026-11-16 Dispute this row
Frazier Life Sciences Management, L.P. 422,505 SH3,823,670 dollarsUnchanged Prior quarter: 422,505Open filing 0001892134-26-000007 Filed 2026-11-16 Dispute this row
VANGUARD CAPITAL MANAGEMENT LLC 198,181 SH1,793,538 dollarsHigher by 19,664 Prior quarter: 178,517Open filing 0002100119-26-001711 Filed 2026-11-13 Dispute this row
Stonepine Capital Management, LLC 189,092 SH1,711,283 dollarsLower by 36,902 Prior quarter: 225,994Open filing 0001440771-26-000027 Filed 2026-11-13 Dispute this row
Sio Capital Management, LLC 152,464 SH1,379,799 dollarsUnchanged Prior quarter: 152,464Open filing 0001214659-26-014302 Filed 2026-11-16 Dispute this row
Merck Co., Inc. 105,982 SH959,137 dollarsUnchanged Prior quarter: 105,982Open filing 0000310158-26-000249 Filed 2026-11-13 Dispute this row
RENAISSANCE TECHNOLOGIES LLC Partly reported under another manager63,553 SH575,155 dollarsLower by 600 Prior quarter: 64,153Open filing 0001037389-26-000062 Filed 2026-11-12 Dispute this row
MORGAN STANLEY Partly reported under another manager53,674 SH485,750 dollarsLower by 3,280 Prior quarter: 56,954Open filing 0000895421-26-000309 Filed 2026-11-13 Dispute this row
GEODE CAPITAL MANAGEMENT, LLC Partly reported under another manager41,449 SH375,140 dollarsHigher by 2,394 Prior quarter: 39,055Open filing 0001214717-26-000012 Filed 2026-11-06 Dispute this row
TWO SIGMA INVESTMENTS, LP 40,104 SH362,941 dollarsHigher by 25,560 Prior quarter: 14,544Open filing 0000899140-26-001341 Filed 2026-11-16 Dispute this row
VANGUARD FIDUCIARY TRUST CO 28,193 SH255,147 dollarsHigher by 5,599 Prior quarter: 22,594Open filing 0000933478-26-000017 Filed 2026-11-13 Dispute this row
BRIDGEWAY CAPITAL MANAGEMENT, LLC 17,544 SH158,773 dollarsUnchanged Prior quarter: 17,544Open filing 0001107261-26-000007 Filed 2026-11-16 Dispute this row
GSA CAPITAL PARTNERS LLP 16,673 SH151 dollarsHigher by 3,083 Prior quarter: 13,590Open filing 0001362033-26-000013 Filed 2026-11-16 Dispute this row
STATE STREET CORP Partly reported under another manager13,311 SH120,465 dollarsUnchanged Prior quarter: 13,311Open filing 0000093751-26-000747 Filed 2026-11-12 Dispute this row
PRUDENTIAL FINANCIAL INC Partly reported under another manager13,180 SH119,279 dollarsNot in the prior quarter’s filings read Open filing 0001137774-26-000233 Filed 2026-11-16 Dispute this row
HRT FINANCIAL LP 12,453 SH112 dollarsNot in the prior quarter’s filings read Open filing 0001475597-26-000249 Filed 2026-11-13 Dispute this row
NORTHERN TRUST CORP Partly reported under another manager11,650 SH105,433 dollarsNot in the prior quarter’s filings read Open filing 0000073124-26-000067 Filed 2026-11-16 Dispute this row
CITADEL ADVISORS LLC Partly reported under another manager11,061 SH100,102 dollarsLower by 14,889 Prior quarter: 25,950Open filing 0001104659-26-128228 Filed 2026-11-16 Dispute this row
BlackRock, Inc. Partly reported under another manager10,908 SH98,718 dollarsHigher by 2,151 Prior quarter: 8,757Open filing 0002012383-26-003985 Filed 2026-11-13 Dispute this row
Vanguard Global Advisers, LLC 3,359 SH30,399 dollarsNot in the prior quarter’s filings read Open filing 0001811242-26-000017 Filed 2026-11-13 Dispute this row
Steward Partners Investment Advisory, LLC 714 SH6,462 dollarsUnchanged Prior quarter: 714Open filing 0001723397-26-000006 Filed 2026-11-13 Dispute this row
UBS Group AG Partly reported under another manager544 SH4,924 dollarsHigher by 530 Prior quarter: 14Open filing 0001610520-26-000121 Filed 2026-11-10 Dispute this row
ROYAL BANK OF CANADA Partly reported under another manager98 SH1,000 dollarsNot in the prior quarter’s filings read Open filing 0001140361-26-044123 Filed 2026-11-16 Dispute this row
Tower Research Capital LLC (TRC) Partly reported under another manager94 SH851 dollarsNot in the prior quarter’s filings read Open filing 0001533421-26-000010 Filed 2026-11-16 Dispute this row
Key Financial Inc 59 SH534 dollarsUnchanged Prior quarter: 59Open filing 0001420506-26-002442 Filed 2026-11-02 Dispute this row
JONES FINANCIAL COMPANIES LLLP Partly reported under another manager58 SH524 dollarsHigher by 29 Prior quarter: 29Open filing 0001193125-26-459442 Filed 2026-11-13 Dispute this row
CITIGROUP INC Partly reported under another manager1 SH9 dollarsNot in the prior quarter’s filings read Open filing 0000831001-26-000052 Filed 2026-11-04 Dispute this row
Managers in the prior quarter with no filing read for the latest

They may simply not have filed yet: absent from the latest quarter’s filings read is not the same as a position sold.

  • Velan Capital Investment Management LP 14,285 SH
  • PRELUDE CAPITAL MANAGEMENT, LLC 11,600 SH
  • SECURITY NATIONAL BANK OF SIOUX CITY IOWA /IA/ 321 SH
  • BARCLAYS PLC 115 SH
  • Form 13F covers long positions in Section 13(f) securities only: no short positions and no securities outside that list.
  • Reports for quarters ending before 2013-06-30 were filed as plain text and are not read.
  • A manager that has not yet filed for the latest quarter is absent, not at zero; filings are due up to 45 days after quarter end.
  • A change is the difference between two quarter-end snapshots, not a trade.
  • A position reported under another manager may also appear in that manager’s filing; rows are not added together.
  • Holdings the securities list cannot place with this company, or places ambiguously, are not shown.

Trades by members of Congress

Periodic transaction reports filed by U.S. House members that name this company’s stock. Dates and amounts are as filed.

No House member’s trade in this company is placed in the store. A trade not yet filed or not linked to a company is absent, not zero.

5% holders (Schedule 13D and 13G)

Schedules filed in the SEC’s structured format (late 2024 onward) are read here. Earlier schedules are free text and are not read.

5% holders, newest event first, as filed
HolderPercent of classShares heldEvent dateFormSource
Coastlands Capital LP Common Stock, par value $0.0001 per share9.99731,573.0009/30/2026 Filed 2026-11-13SCHEDULE 13G/AAmendment 1Open filing 0001104659-26-127419 Dispute this row
Coastlands Capital Partners LP Common Stock, par value $0.0001 per share9.99731,573.0009/30/2026 Filed 2026-11-13SCHEDULE 13G/AAmendment 1Open filing 0001104659-26-127419 Dispute this row
Coastlands Capital GP LLC Common Stock, par value $0.0001 per share9.99731,573.0009/30/2026 Filed 2026-11-13SCHEDULE 13G/AAmendment 1Open filing 0001104659-26-127419 Dispute this row
Coastlands Capital LLC Common Stock, par value $0.0001 per share9.99731,573.0009/30/2026 Filed 2026-11-13SCHEDULE 13G/AAmendment 1Open filing 0001104659-26-127419 Dispute this row
Matthew D. Perry Common Stock, par value $0.0001 per share9.99731,573.0009/30/2026 Filed 2026-11-13SCHEDULE 13G/AAmendment 1Open filing 0001104659-26-127419 Dispute this row
Adage Capital Management, L.P. Common Stock, par value $0.0001 per share7.06464,598.0009/30/2026 Filed 2026-11-12SCHEDULE 13GOpen filing 0000919574-26-007551 Dispute this row
Robert Atchinson Common Stock, par value $0.0001 per share7.06464,598.0009/30/2026 Filed 2026-11-12SCHEDULE 13GOpen filing 0000919574-26-007551 Dispute this row
Phillip Gross Common Stock, par value $0.0001 per share7.06464,598.0009/30/2026 Filed 2026-11-12SCHEDULE 13GOpen filing 0000919574-26-007551 Dispute this row
StemPoint Capital LP Common stock, par value $0.0001 per share9.5628,866.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 2Open filing 0001104659-26-096755 Dispute this row
StemPoint Capital Management GP LLC Common stock, par value $0.0001 per share9.5628,866.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 2Open filing 0001104659-26-096755 Dispute this row
Michelle Ross Common stock, par value $0.0001 per share9.5628,866.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 2Open filing 0001104659-26-096755 Dispute this row
Point72 Asset Management, L.P. Common Stock, par value $0.0001 per share00.0003/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 2Open filing 0000919574-26-003488 Dispute this row
Point72 Capital Advisors, Inc. Common Stock, par value $0.0001 per share00.0003/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 2Open filing 0000919574-26-003488 Dispute this row
Steven A. Cohen Common Stock, par value $0.0001 per share00.0003/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 2Open filing 0000919574-26-003488 Dispute this row
Sirenia Capital Management LP Common Stock, par value $0.0001 per share9.91,142,862.0003/31/2026 Filed 2026-05-15SCHEDULE 13GOpen filing 0000919574-26-003213 Dispute this row
Alex Silverstein Common Stock, par value $0.0001 per share9.91,142,862.0003/31/2026 Filed 2026-05-15SCHEDULE 13GOpen filing 0000919574-26-003213 Dispute this row
BCLS II Equity Opportunities, LP Common Stock, par value $0.0001 per share9.99664,02103/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 4Open filing 0001193125-26-226925 Dispute this row
Bain Capital Life Sciences Fund II, L.P. Common Stock, par value $0.0001 per share0003/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 4Open filing 0001193125-26-226925 Dispute this row
BCIP Life Sciences Associates, LP Common Stock, par value $0.0001 per share0003/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 4Open filing 0001193125-26-226925 Dispute this row
ORBIMED ADVISORS LLC Common Stock, par value $0.0001 per share9.99642,000.0003/31/2026 Filed 2026-05-15SCHEDULE 13GOpen filing 0000947871-26-000552 Dispute this row
OrbiMed Capital GP X LLC Common Stock, par value $0.0001 per share7.49481,500.0003/31/2026 Filed 2026-05-15SCHEDULE 13GOpen filing 0000947871-26-000552 Dispute this row
Bain Capital Life Sciences Fund II, L.P. Common Stock, par value $0.0001 per share1.3992,11112/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 3Open filing 0001193125-26-054804 Dispute this row
BCIP Life Sciences Associates, LP Common Stock, par value $0.0001 per share0.2120,83312/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 3Open filing 0001193125-26-054804 Dispute this row
BCLS II Equity Opportunities, LP Common Stock, par value $0.0001 per share8.56,259,74212/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 3Open filing 0001193125-26-054804 Dispute this row
BCLS II Investco, LP Common Stock, par value $0.0001 per share0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 3Open filing 0001193125-26-054804 Dispute this row
StemPoint Capital LP Common stock, par value $0.0001 per share8.46,030,028.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 1Open filing 0001104659-26-015985 Dispute this row
StemPoint Capital Management GP LLC Common stock, par value $0.0001 per share8.46,030,028.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 1Open filing 0001104659-26-015985 Dispute this row
Michelle Ross Common stock, par value $0.0001 per share8.46,030,028.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 1Open filing 0001104659-26-015985 Dispute this row
Frazier Life Sciences Public Fund, L.P. Common Stock, par value $0.0001 per share6.74,676,472.0012/31/2025 Filed 2026-02-13SCHEDULE 13G/AAmendment 2Open filing 0001231919-26-000149 Dispute this row
FHMLSP, L.P. Common Stock, par value $0.0001 per share6.74,676,472.0012/31/2025 Filed 2026-02-13SCHEDULE 13G/AAmendment 2Open filing 0001231919-26-000149 Dispute this row
FHMLSP, L.L.C. Common Stock, par value $0.0001 per share6.74,676,472.0012/31/2025 Filed 2026-02-13SCHEDULE 13G/AAmendment 2Open filing 0001231919-26-000149 Dispute this row
Frazier Life Sciences X, L.P. Common Stock, par value $0.0001 per share0.2149,060.0012/31/2025 Filed 2026-02-13SCHEDULE 13G/AAmendment 2Open filing 0001231919-26-000149 Dispute this row
FHMLS X, L.P. Common Stock, par value $0.0001 per share0.2149,060.0012/31/2025 Filed 2026-02-13SCHEDULE 13G/AAmendment 2Open filing 0001231919-26-000149 Dispute this row
FHMLS X, L.L.C. Common Stock, par value $0.0001 per share0.2149,060.0012/31/2025 Filed 2026-02-13SCHEDULE 13G/AAmendment 2Open filing 0001231919-26-000149 Dispute this row
Frazier Life Sciences XI, L.P. Common Stock, par value $0.0001 per share0.6396,902.0012/31/2025 Filed 2026-02-13SCHEDULE 13G/AAmendment 2Open filing 0001231919-26-000149 Dispute this row
FHMLS XI, L.P. Common Stock, par value $0.0001 per share0.6396,902.0012/31/2025 Filed 2026-02-13SCHEDULE 13G/AAmendment 2Open filing 0001231919-26-000149 Dispute this row
FHMLS XI, L.L.C. Common Stock, par value $0.0001 per share0.6396,902.0012/31/2025 Filed 2026-02-13SCHEDULE 13G/AAmendment 2Open filing 0001231919-26-000149 Dispute this row
Frazier Life Sciences XII, L.P. Common Stock, par value $0.0001 per share1.0692,657.0012/31/2025 Filed 2026-02-13SCHEDULE 13G/AAmendment 2Open filing 0001231919-26-000149 Dispute this row
FHMLS XII, L.P. Common Stock, par value $0.0001 per share1.0692,657.0012/31/2025 Filed 2026-02-13SCHEDULE 13G/AAmendment 2Open filing 0001231919-26-000149 Dispute this row
FHMLS XII, L.L.C. Common Stock, par value $0.0001 per share1.0692,657.0012/31/2025 Filed 2026-02-13SCHEDULE 13G/AAmendment 2Open filing 0001231919-26-000149 Dispute this row
James N. Topper Common Stock, par value $0.0001 per share0.2149,060.0012/31/2025 Filed 2026-02-13SCHEDULE 13G/AAmendment 2Open filing 0001231919-26-000149 Dispute this row
Patrick J. Heron Common Stock, par value $0.0001 per share0.2149,060.0012/31/2025 Filed 2026-02-13SCHEDULE 13G/AAmendment 2Open filing 0001231919-26-000149 Dispute this row
GILEAD SCIENCES, INC. Common Stock, par value $0.0001 per share19.914,517,67812/31/2025 Filed 2026-02-12SCHEDULE 13G/AAmendment 3Open filing 0001123292-26-000166 Dispute this row
Coastlands Capital LP Common Stock, par value $0.0001 per share9.995,346,069.0012/04/2025 Filed 2025-12-11SCHEDULE 13GOpen filing 0001104659-25-120365 Dispute this row
Coastlands Capital Partners LP Common Stock, par value $0.0001 per share9.995,346,069.0012/04/2025 Filed 2025-12-11SCHEDULE 13GOpen filing 0001104659-25-120365 Dispute this row
Coastlands Capital GP LLC Common Stock, par value $0.0001 per share9.995,346,069.0012/04/2025 Filed 2025-12-11SCHEDULE 13GOpen filing 0001104659-25-120365 Dispute this row
Coastlands Capital LLC Common Stock, par value $0.0001 per share9.995,346,069.0012/04/2025 Filed 2025-12-11SCHEDULE 13GOpen filing 0001104659-25-120365 Dispute this row
Matthew D. Perry Common Stock, par value $0.0001 per share9.995,346,069.0012/04/2025 Filed 2025-12-11SCHEDULE 13GOpen filing 0001104659-25-120365 Dispute this row
ADAR1 Capital Management, LLC Common Stock, par value $0.0001 per share9.3381,000.0009/30/2025 Filed 2026-11-16SCHEDULE 13GOpen filing 0001104659-26-128741 Dispute this row
Daniel Schneeberger Common Stock, par value $0.0001 per share9.3381,000.0009/30/2025 Filed 2026-11-16SCHEDULE 13GOpen filing 0001104659-26-128741 Dispute this row

Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.

What was read

2,660,713 filings read, dated 2004-06-14 to 2026-11-19: Forms 3, 3/A, 4, 4/A, 5, 5/A.

Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.

Filings read, by filing year
Filing yearFilings read
201577,800
2016222,642
2017222,009
2018223,345
2019216,482
2020226,343
2021249,835
2022231,682
2023229,674
2024234,045
2025235,520
2026263,123

Filings made before the SEC required XML are listed, not extracted.

Back to Xilio Therapeutics, Inc.